| 10.07 0.07 (0.7%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.59 | 1-year : | 13.17 |
| Resists | First : | 10.78 | Second : | 11.27 |
| Pivot price | 10.58  |
|||
| Supports | First : | 9.97 | Second : | 8.29 |
| MAs | MA(5) : | 10.15 |
MA(20) : | 10.73 |
| MA(100) : | 10.04  |
MA(250) : | 9.98 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.4 |
D(3) : | 8.6 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 11.35 | Low : | 8.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HLN ] has closed above bottom band by 17.8%. Bollinger Bands are 93.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.25 - 10.32 | 10.32 - 10.38 |
| Low: | 9.9 - 9.99 | 9.99 - 10.07 |
| Close: | 9.94 - 10.07 | 10.07 - 10.2 |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Thu, 12 Mar 2026
Haleon announces £500 million share buyback program across multiple exchanges - Investing.com India
Thu, 12 Mar 2026
Haleon (NYSE: HLN) starts £500m buyback to cancel shares by Aug 2026 - Stock Titan
Thu, 12 Mar 2026
New parodontax toothpaste and mouthwash aim to protect gums daily - Stock Titan
Thu, 12 Mar 2026
Haleon kicks off planned GBP500 million buyback - marketscreener.com
Thu, 12 Mar 2026
Orion Porfolio Solutions LLC Sells 103,908 Shares of Haleon PLC Sponsored ADR $HLN - MarketBeat
Thu, 12 Mar 2026
Haleon PLC Sponsored ADR (NYSE:HLN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4,450 (M) |
| Shares Float | 8,840 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 12.7 (%) |
| Shares Short | 18,580 (K) |
| Shares Short P.Month | 19,930 (K) |
| EPS | 0.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.47 |
| Profit Margin | 15.1 % |
| Operating Margin | 22.9 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 10.2 % |
| Qtrly Rev. Growth | 0.6 % |
| Gross Profit (p.s.) | 1.6 |
| Sales Per Share | 2.47 |
| EBITDA (p.s.) | 0.61 |
| Qtrly Earnings Growth | 92 % |
| Operating Cash Flow | 2,630 (M) |
| Levered Free Cash Flow | 1,370 (M) |
| PE Ratio | 20.55 |
| PEG Ratio | 0 |
| Price to Book value | 4.07 |
| Price to Sales | 4.06 |
| Price to Cash Flow | 17.03 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|